Bright Light Therapy for Non-motor Symptoms in Parkinson's Disease
NCT ID: NCT05524961
Last Updated: 2025-04-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
69 participants
INTERVENTIONAL
2022-12-09
2025-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Light Therapy in Parkinson's Disease
NCT06129942
Bright Light Therapy for Non-motor Symptoms in Parkinson's Disease
NCT02909192
Light Therapy in Parkinson's Disease
NCT02072642
Light Therapy for PD - Dose Selection
NCT04291014
Effect of Bright Light on Mood and Sleep in Parkinson's Disease
NCT01604876
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The secondary aims of the study are to examine the effect of timed-BLT on other non-motor symptoms, including depression, fatigue; and the quality of life.
Additional analyses will be carried out to examine the efficacy of the timed-placebo as compared to the random-time placebo (placebo group).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Timed-Bright light therapy (BLT group)
10,000lux bright light
Bright light therapy
Regularly-timed exposure to 10,000lux bright light therapy for 60minutes a day for six weeks
Timed-inactivated negative ion generator (Active-control group)
Inactivated negative ion generator
Inactivated negative ion generator
Regularly-timed exposure to an inactivated negative ion generator for 60minutes a day for six weeks
Random-time inactivated negative ion generator (placebo group)
Inactivated negative ion generator
Inactivated negative ion generator
Randomly-timed exposure to an inactivated negative ion generator for 60minutes a day for six weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bright light therapy
Regularly-timed exposure to 10,000lux bright light therapy for 60minutes a day for six weeks
Inactivated negative ion generator
Regularly-timed exposure to an inactivated negative ion generator for 60minutes a day for six weeks
Inactivated negative ion generator
Randomly-timed exposure to an inactivated negative ion generator for 60minutes a day for six weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Capable to give informed consent
3. Maintained on stable dose of medications for Parkinson's disease/psychotropic drugs for at least four weeks prior to entry of the study
4. Score 14 or more on the Epworth Sleepiness Scale
Exclusion Criteria
2. Unstable medical or psychiatric condition
3. Presence of substantial suicidal risk as judged by the clinician and/or screening instruments
4. Presence of active psychotic symptoms that might impair the ability to consent or validity of the interview
5. Cognitive impairment with score of 19 or below by the Hong Kong version of Montreal Cognitive Assessment (HK-MoCA)
6. Contraindication to bright light therapy: history of light induced migraine. Epilepsy, current use of photosensitizing medications, presence of eye disease, e.g. retinal disease, severe cataract, glaucoma and blindness
7. Significant medical condition/ hearing impairment/ speech deficit lead to incapability in completing clinical interview
8. Regular shift worker or trans-meridian flight in the past three months
9. Enrolment in another clinical trial of an investigational medicinal product or device
10. Subjects who are on exogenous melatonin
11. Patients with deep brain stimulation (DBS) implant
12. Patients with known sleep disorders, eg. untreated severe sleep apnea, restless leg syndrome
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chinese University of Hong Kong
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Joey WY Chan
Clinical Associate Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Chinese University of Hong Kong
Hong Kong, , Hong Kong
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021.676T
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.